和黃醫藥(00013.HK)將於2025年世界肺癌大會和中國臨牀腫瘤學會2025年年會公佈數據
格隆匯9月5日丨和黃醫藥(00013.HK)宣佈將於2025年9月6日至9日在西班牙巴塞羅那召開的2025年世界肺癌大會(WCLC),以及2025年9月10至14日在中國濟南召開的中國臨牀腫瘤學會(“CSCO”)2025年年會上公佈和黃醫藥自主研發的化合物的數項研究的最新及更新後的敷據。
賽沃替尼用於治療非小細胞肺癌的SACHI研究、SAVANNAH研究以及一項Ib期驗證性研究的最新分析結果將於2025年世界肺癌大會公佈。賽沃替尼是一種強效、高選擇性的口服MET酪氨酸激酶抑制劑(ГTKI),由阿斯利康與和黃醫藥共同開發,並由阿斯利康商業化。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.